CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

A&G Pharmaceutical is a theranostics company creating and developing monoclonal antibodies to cancer-specific targets as a basis for novel therapeutic and diagnostic products. The company is currently advancing a near-term opportunity to develop and commercialize a line of diagnostic test kits that will improve early detection, diagnosis, and treatment of breast cancer based on GP88, a patented and proprietary growth factor discovered by A&G researchers. Concurrently, A&G's therapeutic division is pursuing development of anti-GP88 monoclonal antibody therapeutics for cancer. A&G's customized antibody service generates revenue to fund the drug development effort by accelerating the generation of novel, functional antibody therapeutics for leading pharmaceutical and biotechnology companies as well as federal laboratories. A&G has raised $3.5 million of equity capital and is located in Columbia, Md.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

American Diagnostica, Inc., part of Sekisui Chemical Co., Ltd., is a company headquartered in Stamford, CT, that manufactures and sells medicines. On April 21, 2009 Sekisui America Corp. acquired American Diagnostica, Inc.

Medigen Biotechnology was established at the end of 1999. The company adheres to the vision of “Innovation makes life better” and focuses on the development of new products in the two major areas of “hepatopathy” and “cancer” in Asia. Through years of hard work, Keya Biotech has gradually developed into a comprehensive biopharmaceutical group, and its business has covered: new drug clinical development, innovative biomedical research and development platform, molecular detection, cell culture vaccine technology, and scientific name drug production and marketing. And many other businesses.

Mor Research Applications is the Technology Transfer Office of Clalit Health Services, the largest HMO in Israel, providing end-to-end technology transfer services. MOR helps inventors translate new ideas in the medical, pharmaceutical, diagnostics, medical IT, and biotechnology areas into products and solutions that benefit healthcare providers and patients.

Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer. Its cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Its lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by Epigenomics itself. The concept of its diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification.

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services globally to companies within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS technology (IVRS/IXRS) through to commercial-scale manufacture and companion diagnostic development.Only Almac can combine the expertise, from their specialised teams, to provide you with the right service solutions to help you across the full biopharmaceutical product lifecycle, from the preclinical stages through to commercialisation. They are a privately owned organisation that has organically grown over 40 years and now employs in excess of 4,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo). Through our continual investment in the development of our state of the art services; from cutting edge biomarker and companion diagnostics through to step changes in the management of the clinical trial data and the clinical supply chain to biocatalytic manufacture of API, Almac ensures they are always there to support you across the product development lifecycle.

BioMedica Diagnostics, Inc. is a private company headquartered in Windsor, NS, Canada, that provides diagnostic solutions.

Roche Diagnostics GmbH, part of Roche Holding AG, is a company headquartered in Mannheim, Germany, involved in laboratory analytical instruments. Andreas Schmitz and Claus Haberda are the current co-CEOs of the firm. On January 01, 1999 Roche Holding AG acquired Roche Diagnostics GmbH.

Trustees of Dartmouth College, part of Dartmouth College, is a company headquartered in Hanover, NH. The firm operates higher education institutes. It was founded in 1769.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Kunshan Industrial Technology Research Institute Small Nucleic Acid Biotechnology Research Institute Co., Ltd., established on 2008-10-29, The scope of business includes the transformation of scientific and technological achievements,Project development and introduction,Investment,technical consulting,Technical Services;Import and export business of goods and technology,law,Administrative regulations stipulate pre-licensing operations,Except for prohibited operations;Research on nucleic acid technology and development of related products,Sales;lease of own home,Experimental equipment rental;account Serive.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Guangdong General Hospital (Chinese: 广东省人民医院 meaning "Guangdong Provincial People's Hospital") is a large hospital, founded in 1946, located in Yuexiu District, Guangzhou, Guangdong, China.

Genomic Health, Inc. (NASDAQ: GHDX) is a provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.

Guangzhou Jerke Biotechnology Co., Ltd., established on 2013-01-15, Business scope includes medical research and experimental development;drug development;Biotechnology Extension Services;Biotechnology Development Services;Biotechnology Consulting,communication service;Biotechnology Transfer Services;Operation of non-licensed medical devices(i.e. no application required<Medical device operating enterprise license>ready-to-operate medical device",Including Class I medical devices and national regulations do not require application<Medical device operating enterprise license>Ready-to-operate Class II Medical Devices);Medical supplies and equipment retail(Does not contain drugs and medical devices);

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN.